Birchview Capital LP increased its position in Prothena Co. plc (NASDAQ:PRTA - Free Report) by 45.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 304,574 shares of the biotechnology company's stock after acquiring an additional 95,000 shares during the quarter. Prothena comprises approximately 3.4% of Birchview Capital LP's holdings, making the stock its 5th biggest position. Birchview Capital LP owned about 0.57% of Prothena worth $4,218,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in PRTA. Barclays PLC increased its stake in shares of Prothena by 110.2% in the third quarter. Barclays PLC now owns 95,222 shares of the biotechnology company's stock worth $1,592,000 after purchasing an additional 49,916 shares in the last quarter. SG Americas Securities LLC increased its stake in Prothena by 167.0% in the 4th quarter. SG Americas Securities LLC now owns 37,612 shares of the biotechnology company's stock worth $521,000 after buying an additional 23,525 shares in the last quarter. Duncan Williams Asset Management LLC raised its holdings in Prothena by 41.9% during the fourth quarter. Duncan Williams Asset Management LLC now owns 69,199 shares of the biotechnology company's stock valued at $958,000 after acquiring an additional 20,450 shares during the period. Rhumbline Advisers lifted its position in shares of Prothena by 1.8% in the fourth quarter. Rhumbline Advisers now owns 67,115 shares of the biotechnology company's stock valued at $930,000 after acquiring an additional 1,175 shares in the last quarter. Finally, Focused Wealth Management Inc bought a new position in shares of Prothena in the fourth quarter worth about $445,000. Institutional investors own 97.08% of the company's stock.
Analyst Upgrades and Downgrades
Several analysts recently issued reports on the company. Oppenheimer lifted their target price on Prothena from $58.00 to $62.00 and gave the company an "outperform" rating in a research note on Friday, February 7th. Royal Bank of Canada reduced their price objective on shares of Prothena from $24.00 to $20.00 and set a "sector perform" rating on the stock in a research report on Friday, February 21st. Chardan Capital restated a "buy" rating and set a $40.00 target price on shares of Prothena in a research report on Friday, February 21st. StockNews.com upgraded shares of Prothena from a "sell" rating to a "hold" rating in a report on Monday, February 24th. Finally, Piper Sandler boosted their price target on shares of Prothena from $94.00 to $110.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $55.00.
Check Out Our Latest Report on PRTA
Prothena Stock Performance
Shares of NASDAQ:PRTA traded down $0.05 on Monday, reaching $9.65. The company's stock had a trading volume of 573,554 shares, compared to its average volume of 500,906. The company has a 50-day simple moving average of $12.34 and a 200 day simple moving average of $14.11. The company has a market cap of $519.43 million, a P/E ratio of -4.20 and a beta of 0.07. Prothena Co. plc has a 52-week low of $9.00 and a 52-week high of $25.42.
Prothena (NASDAQ:PRTA - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.06). Prothena had a negative return on equity of 22.67% and a negative net margin of 90.50%. The company had revenue of $2.12 million for the quarter, compared to the consensus estimate of $7.53 million. On average, equities research analysts forecast that Prothena Co. plc will post -4.04 EPS for the current fiscal year.
Prothena Company Profile
(
Free Report)
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
Featured Stories
Before you consider Prothena, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prothena wasn't on the list.
While Prothena currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
